Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

Open access

Abstract

BACKGROUND: Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been used for various benign tumours associated with tuberous sclerosis complex. We assessed the efficacy and safety of two trough exposure concentrations of everolimus, 3-7 ng/mL (low exposure) and 9-15 ng/mL (high exposure), compared with placebo as adjunctive therapy for treatment-resistant focal-onset seizures in tuberous sclerosis complex. METHODS: In this phase 3, randomised, double-blind, placebo-controlled study, eligible patients aged 2-65 years with tuberous sclerosis complex and treatment-resistant seizures (≥16 in an 8-week baseline phase) receiving one to three concomitant antiepileptic drugs were recruited from 99 centres across 25 countries. Participants were randomly assigned (1:1:1), via permuted-block randomisation (block size of six) implemented by Interactive Response Technology software, to receive placebo, low-exposure everolimus, or high-exposure everolimus. Randomisation was stratified by age subgroup (<6 years, 6 to <12 years, 12 to <18 years, and ≥18 years). Patients, investigators, site personnel, and the sponsor's study team were masked to treatment allocation. The starting dose of everolimus depended on age, body-surface area, and concomitant use of cytochrome 3A4/P-glycoprotein inducers. Dose adjustments were done to attain target trough ranges during a 6-week titration period, and as needed during a 12-week maintenance period of core phase. Patients or their caregivers recorded events in a seizure diary throughout the study. The primary endpoint was change from baseline in the frequency of seizures during the maintenance period, defined as response rate (the proportion of patients achieving ≥50% reduction in seizure frequency) and median percentage reduction in seizure frequency, in all randomised patients. This study is registered with ClinicalTrials.gov, number NCT01713946. FINDINGS: Between July 3, 2013, and May 29, 2015, 366 patients were enrolled and randomly assigned to placebo (n=119), low-exposure everolimus, (n=117), or high-exposure everolimus (n=130). The response rate was 15·1% with placebo (95% CI 9·2-22·8; 18 patients) compared with 28·2% for low-exposure everolimus (95% CI 20·3-37·3; 33 patients; p=0·0077) and 40·0% for high-exposure everolimus (95% CI 31·5-49·0; 52 patients; p<0·0001). The median percentage reduction in seizure frequency was 14·9% (95% CI 0·1-21·7) with placebo versus 29·3% with low-exposure everolimus (95% CI 18·8-41·9; p=0·0028) and 39·6% with high-exposure everolimus (95% CI 35·0-48·7; p<0·0001). Grade 3 or 4 adverse events occurred in 13 (11%) patients in the placebo group, 21 (18%) in the low-exposure group, and 31 (24%) in the high-exposure group. Serious adverse events were reported in three (3%) patients who received placebo, 16 (14%) who received low-exposure everolimus, and 18 (14%) who received high-exposure everolimus. Adverse events led to treatment discontinuation in two (2%) patients in the placebo group versus six (5%) in the low-exposure group and four (3%) in the high-exposure group. INTERPRETATION: Adjunctive everolimus treatment significantly reduced seizure frequency with a tolerable safety profile compared with placebo in patients with tuberous sclerosis complex and treatment-resistant seizures. FUNDING: Novartis Pharmaceuticals Corporation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(16)31419-2

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trial profi le
Figure 1 Trial profi leCC-BY-NC-ND · From the PDF
Figure 2 Seizure outcomes (A) Response rate by treatment group. Bars represent 95% CIs. (B) Median percentage reduction in seizure frequency by treatment group. Bars represent 95% CIs. (C) Distribution of reduction from baseline in seizure frequency by treatment group. (D) Response rate among various seizure types. Numbers on the x axis denote the number of patients with at least one occurrence of the seizure type during the baseline phase; bars represent 95% CIs. (E) Median percentage change from baseline in seizure frequency. (F) Median percentage of seizure-free days.
Figure 2 Seizure outcomes (A) Response rate by treatment group. Bars represent 95% CIs. (B) Median percentage reduction in seizure frequency by treatment group. Bars represent 95% CIs. (C) Distribution of reduction from baseline in seizure frequency by treatment group. (D) Response rate among various seizure types. Numbers on the x axis denote the number of patients with at least one occurrence of the seizure type during the baseline phase; bars represent 95% CIs. (E) Median percentage change from baseline in seizure frequency. (F) Median percentage of seizure-free days.CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 796

Metadata

Authors
French, J. A., Lawson, J. A., Yapici, Z., Ikeda, H., Polster, T., Nabbout, R., Curatolo, P., de Vries, P. J., Dlugos, D. J., Berkowitz, N., Voi, M., Peyrard, S., Pelov, D., & Franz, D. N.
Affiliations
  • NYU Langone Health (US)
  • Sydney Children's Hospital (AU)
  • National Epilepsy Center (JP)
  • Krankenhaus Mara (DE)
  • Hôpital Necker-Enfants Malades (FR)
  • Policlinico Tor Vergata (IT)
  • Children's Hospital of Philadelphia (US)
  • Cincinnati Children's Hospital Medical Center (US)
Corresponding author
French, Jacqueline A
Venue
The Lancet
Publisher
Elsevier BV
Published
2016-10
Volume
388
Issue
10056
Pages
2153-2163
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2511912940
Cited by
764
References
31
Citations by year
2026: 55 · 2025: 75 · 2024: 57 · 2023: 78 · 2022: 76 · 2021: 97 · 2020: 108 · 2019: 73 · 2018: 65 · 2017: 69 · 2016: 10
FWCI
58.25
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
  • INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
Funders
Novartis Pharmaceuticals Corporation
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
Keywords
everolimus, tuberous sclerosis complex, focal seizures, drug-resistant epilepsy, adjunctive antiepileptic therapy, mTOR inhibitors, seizure frequency reduction, antiepileptic drug interactions, adverse events, pharmacovigilance
MeSH terms
Everolimus, Adolescent, Adult, Aged, Anticonvulsants, Antineoplastic Agents, Child, Child, Preschool, Combined Modality Therapy, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Seizures, Tuberous Sclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. https://app.cochat.ai/papers/10.1016/s0140-6736(16)31419-2
The paper
French, J. A., Lawson, J. A., Yapici, Z., Ikeda, H., Polster, T., Nabbout, R., Curatolo, P., de Vries, P. J., Dlugos, D. J., Berkowitz, N., Voi, M., Peyrard, S., Pelov, D., & Franz, D. N. (2016). Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. The Lancet. https://doi.org/10.1016/s0140-6736(16)31419-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.